FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and medicine, namely to telavancin salt with isethionic acid containing from 12 to 20 wt.% of isethionic acid. Invention also includes lyophilised pharmaceutical compositions containing a therapeutically effective amount of telavancin isethionate of formula 1, which can be used to treat infections caused by gram-positive bacteria sensitive to telavancin.
EFFECT: telavancin salt with isethionic acid has excellent physical and chemical properties, good water solubility and is less susceptible to decomposition processes compared to hydrochloride during production, purification and storage, has high antibacterial activity.
9 cl, 5 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTITUMOUR ANTHRAFURANDIONE AND BASED PHARMACEUTICAL COMPOSITIONS | 2014 |
|
RU2554939C1 |
| ANTIFUNGAL SEMI-SYNTHETIC POLYENE ANTIBIOTIC, WATER-SOLUBLE SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS BASED THEREON | 2018 |
|
RU2688658C1 |
| ANTICANCER PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATING BREAST CANCER | 2015 |
|
RU2581022C1 |
| DAPTOMYCIN PREPARATIONS | 2018 |
|
RU2770366C2 |
| LYOPHILISED PREPARATION OF CYTOTOXIC DIPEPTIDES | 2012 |
|
RU2597154C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITIONS BASED ON 1,2-DIHYDROPYRIDINE COMPOUNDS | 2019 |
|
RU2824582C2 |
| PHARMACEUTICAL ANTITUMOR COMPOSITION BASED ON SALT OLIVOMICINE DERIVATIVE | 2017 |
|
RU2662087C1 |
| LYOPHILIZED COMPOSITION | 1999 |
|
RU2268045C2 |
| COMPOSITION FOR PARENTERAL ADMINISTRATION CONTAINING SIPONIMOD | 2018 |
|
RU2803937C2 |
| ALBUMIN-BINDING PRODRUGS BASED ON AURISTATIN E DERIVATIVES | 2018 |
|
RU2795101C2 |
